** Shares in Genmab GMAB.CO fall 5.4% after Johnson & Johnson JNJ.N opted out of further clinical development of the Hexabody-CD38 cancer drug on Monday
** Van Lanschot Kempen says that Hexabody did not differentiate enough from Darzalex, the company's flagship drug, and neither Genmab nor J&J will take the project forward
** While Kempen says "the shares are now free to perform" without this overhang, Jyske Bank does not expect a quick rebound but rather a slow regain of market confidence
** Kempen expects continued earnings momentum and growing appreciation for another cancer drug Epkinly as a major growth driver
** Genmab says J&J opt-out does not impact its 2025 guidance
(Reporting by Vera Dvorakova and Jesus Calero)
((vera.dvorakova@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。